TABLE 2

Lack of Correlation Between Hematologic Toxicity Grade and Pharmacokinetic and Dosimetric Measures in Phase 3 Trial of ⁹⁰Y-Ibritumomab Tiuxetan (n = 72)

Measure	Grade of hematologic toxicity (nadir)			P
Measure	0–2	3	4	P
Blood half-life (h)
Neutropenia	27	30	27	0.08
Thrombocytopenia	27	28	29	0.38
Blood residence time (h)
Neutropenia	25	30	27	0.43
Thrombocytopenia	26	27	23	0.95
Blood-derived RM dose (Gy)
Neutropenia	0.66	0.82	0.70	0.22
Thrombocytopenia	0.69	0.71	0.59	0.80
Image-derived RM dose (Gy)
Neutropenia	1.02	1.15	1.16	0.64
Thrombocytopenia	1.01	1.10	1.32	0.26
Total body dose (cGy)
Neutropenia	0.59	0.61	0.22	0.34
Thrombocytopenia	0.58	0.61	0.57	0.13

RM = red marrow.
Data are from Wiseman et al. (11).